|
|
| Lantheus Receives U.S. FDA Approval of PYLARIFY® (piflufolastat F 18) Injection, the First and Only Commercially Available PSMA PET Imaging Agent for Prostate Cancer
|
| Press Release
|
| Lantheus Holdings, Inc., an established leader and fully integrated provider of innovative imaging diagnostics, targeted therapeutics, and artificial intelligence solutions to find, fight and follow serious medical conditions, announced that the U.S. Food and Drug Administration (FDA) has approved PYLARIFY, an F 18-labeled prostate-specific membrane antigen (PSMA) targeted positron emission tomography (PET) imaging agent to identify suspected metastasis or recurrence of prostate cancer.
|
|
|
|
|
|
|
|
|
|
|
PEER-TO-PEER CLINICAL CONVERSATIONS |
|
|
|
|
|
|
CONDOR: Study of 18F-DCFPyL PET/CT Imaging in Patients with Suspected Recurrence of Prostate Cancer
|
A. Oliver Sartor, MD and Michael Morris, MD
Michael Morris, Oliver Sartor, and Alicia Morgans discuss the CONDOR study, the second of two prospective clinical trials designed in collaboration with the FDA to demonstrate the diagnostic performance of PyL in patients with biochemically recurrent prostate cancer.
|
|
|
|
|
|
|
|
|
|
|
| Diagnostic Molecular Imaging for Prostate Cancer in the United States: A Focus on Lesion Localization and Distribution Using 18F-DCFPyL PET/CT at Biochemical Recurrence Lecture & Discussion |
|
Andrei Iagaru, MD, FACNM
|
| Andrei Iagaru joins Phillip Koo, Alicia Morgans, and Neal Shore, in this Independent Medical Education program titled, A Step Towards Personalized Medicine: PSMA PET Imaging in Prostate Cancer, a discussion on Diagnostic Molecular Imaging for Prostate Cancer in the United States.
|
|
|
|
|
|
|
|
|
|
|
|
| [18F]DCFPyL PET/CT in Detection and Localization of Recurrent Prostate Cancer Following Prostatectomy Including Low PSA 0.5 ng/mL - Beyond the Abstract |
| Elisa Perry, Arpit Talwar, Kim Taubman, Michael Ng, Lih-Ming Wong, Russell Booth, Tom Sutherland |
| The aim of this retrospective multicenter analysis was to assess the performance of [18F]DCFPyL prostate-specific membrane antigen (PSMA) PET/CT in the detection and localization of recurrent prostate cancer following radical prostatectomy (RP). |
|
|
|
|
|
| A Prospective Phase II/III Study of PSMA-Targeted 18F-DCFPyL-PET/CT in Patients with Prostate Cancer (PCa) (OSPREY): A Subanalysis of Disease Staging Changes in PCa Patients with Recurrence or Metastases on Conventional Imaging
|
| Jeremy Durack, MD, MS
|
| Jeremy Durack reports on the impact of 18F-DCFPyL on the staging of patients with prostate cancer recurrence or metastases on conventional imaging. On the basis of these data, the authors conclude that 18F-DCFPyL-PET/CT may be a useful tool in staging men with both metastatic and nonmetastatic relapsed prostate cancer.
|
|
|
|
|
|
| Clinical Utility of Preoperative PSMA-Targeted 18F-DCFPyL PET/CT in Men with High-Risk Prostate Cancer: Diagnostic Performance Comparisons with Pelvic CT or MRI in the OSPREY Prospective, Multi-center Trial
|
| Preston Sprenkle, MD
|
| Preston Sprenkle presents initial results of the OSPREY trial, a Study of 18F-DCFPyL PET/CT Imaging in Patients With Prostate Cancer (OSPREY), assessing the clinical utility of preoperative PSMA-targeted 18F-DCFPyL PET/CT in men with high-risk prostate cancer.
|
|
|
|
|
|
|
|
|
|
|
